Kyowa Hakko Kirin

NCT00346632

An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia

NCT00457782

A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

NCT00575562

Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer

NCT00775502

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

NCT00952094

Pharmacokinetic, Pharmacodynamic and Safety Evaluation After Single Oral Administration of KRN1493

NCT00830674

A Study of KRN23 in X-linked Hypophosphatemia

NCT00938288

A Study of KW-3357 in Congenital Antithrombin Deficiency

NCT00921336

Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor

NCT01199367

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

NCT01279291

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

NCT01447732

Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors

NCT02181699

Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

NCT02174250

The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.

NCT02127476

A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease

NCT02256033

Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline

NCT02301130

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

NCT02358473

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

NCT02609477

A Study to Evaluate Abuse Potential of Istradefylline

NCT02867007

KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT04147910

Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-KW-6356

NCT03915405

KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

NCT04190654

Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite

NCT05027646

Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.

NCT05414500

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

NCT06266299

A Study of KK2269 in Adult Participants With Solid Tumors

NCT07192471

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma